D.E. Shaw & Co
LXEO icon

D.E. Shaw & Co’s Lexeo Therapeutics LXEO Stock Holding History

D.E. Shaw & Co’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Sell
30,477
-449,728
-94% -$3.19M ﹤0.01% 4225
2025
Q4 		$4.77M Buy
480,205
+467,387
+3,646% +$4.26M ﹤0.01% 2347
2025
Q3 		$85.1K Buy
+12,818
New +$62K ﹤0.01% 4368

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's LXEO Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Lexeo Therapeutics (LXEO) stake by 94% in Q1 2026, selling an estimated $3.19M and leaving 30,477 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #4225.

D.E. Shaw & Co first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.77M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • D.E. Shaw & Co held 30,477 shares of Lexeo Therapeutics worth $175K as of Q1 2026.
  • D.E. Shaw & Co sold 449,728 Lexeo Therapeutics shares in Q1 2026, an estimated $3.19M.
  • Lexeo Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4225 holding.
  • D.E. Shaw & Co first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • D.E. Shaw & Co's Lexeo Therapeutics position peaked at $4.77M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.